These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Bcl-XL antisense oligodeoxynucleotide sensitizes human esophageal cancer cell line to 5-fluorouracil].
    Author: Zhang L, Wen HT, Wang LX, Zhang L, Zhang YH.
    Journal: Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):173-7. PubMed ID: 16875599.
    Abstract:
    OBJECTIVE: To investigate the effects of the Bcl-XL antisense oligodeoxynucleotides (ASODN) in suppressing the Bcl-XL expression and increasing the sensitivity of esophageal cancer cell line EC9706 to 5-fluorouracil (5-Fu). METHODS: The proliferation inhibitory rate of EC9706 was assessed by MTT, the expression of Bcl-XL was detected by RT-PCR and Western blot, and the apoptotic changes were examined by acridine orange (AO) fluorescent staining and flow cytometry, respectively. RESULTS: In the group of ASODN combined with 5-Fu, the proliferation inhibitory rate of esophageal cancer cells was 71.58%, the expression inhibitory rate of Bcl-XL mRNA was 81.25%, the expression of Bcl-XL protein was decreased significantly. The apoptosis rates detected by AO fluorescent staining and flow cytometry were 69.5% and (63.32 +/- 9.23)%, respectively. There were significant differences as compared with the cell control group, the vacuity control group, the N-ODN group, the ASODN group and the 5-Fu group, respectively (P < 0.05). CONCLUSION: Bcl-XL ASODN combined with 5-Fu can effectively inhibit the proliferation of esophageal cancer cells in vitro. Bcl-XL ASODN can significantly increase the sensitivity of esophageal cancer cells to 5-Fu through suppressing the expression of Bcl-XL.
    [Abstract] [Full Text] [Related] [New Search]